ALS vs FTD: Comparative Investment Analysis

ALS vs Frontotemporal Dementia: Comparative Investment Analysis

Overview

This page provides a comparative investment analysis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two related neurodegenerative diseases that share common pathological features and overlapping therapeutic approaches. The analysis examines clinical trial activity, pharmaceutical company investment, and therapeutic pipeline developments for both conditions.

This comparative analysis examines the investment landscapes of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two neurodegenerative disorders linked by clinical, genetic, and pathological overlap. The analysis compares trial activity, sponsor engagement, therapeutic mechanism coverage, and funding gaps to identify cross-disease investment opportunities and inform strategic prioritization. [@clinicaltrialsgov]

Executive Summary

This page provides a side-by-side comparison of the R&D investment landscape for [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia), two devastating neurodegenerative conditions that share clinical, genetic, and pathological overlaps. Data is sourced from the local [Clinical Trials Index](/clinical-trials) pipeline snapshot refreshed on `2026-03-12T04:24:37`. [@clinicaltrialsgova]

--- [@als]

Portfolio Metrics Comparison

ALS vs Frontotemporal Dementia: Comparative Investment Analysis

Overview

This page provides a comparative investment analysis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two related neurodegenerative diseases that share common pathological features and overlapping therapeutic approaches. The analysis examines clinical trial activity, pharmaceutical company investment, and therapeutic pipeline developments for both conditions.

This comparative analysis examines the investment landscapes of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two neurodegenerative disorders linked by clinical, genetic, and pathological overlap. The analysis compares trial activity, sponsor engagement, therapeutic mechanism coverage, and funding gaps to identify cross-disease investment opportunities and inform strategic prioritization. [@clinicaltrialsgov]

Executive Summary

This page provides a side-by-side comparison of the R&D investment landscape for [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia), two devastating neurodegenerative conditions that share clinical, genetic, and pathological overlaps. Data is sourced from the local [Clinical Trials Index](/clinical-trials) pipeline snapshot refreshed on `2026-03-12T04:24:37`. [@clinicaltrialsgova]

--- [@als]

Portfolio Metrics Comparison

| Metric | ALS | FTD | Differential | [@association]
|---|---:|---:|---:|
| Total tracked trials | 1,568 | 380 | ALS has 4.1x more trials |
| Active trials (recruiting/active/not-yet-recruiting) | 454 (29.0%) | 137 (36.1%) | FTD has higher active proportion |
| Completed trials | 746 (47.6%) | 172 (45.3%) | Similar completion rates |
| Late-stage representation (Phase 3/4) | 140 (8.9%) | 23 (6.1%) | ALS has 46% more late-stage trials |
| Biomarker-forward programs | 124 (7.9%) | 67 (17.6%) | FTD has 2.2x more biomarker trials |
| Combination-therapy signals | 0 (0.0%) | 0 (0.0%) | Both lacking |

Key Insights

Trial Status Distribution

Side-by-Side Comparison

| Category | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---|---:|---:|---:|
| Active/Recruiting | 454 | 29.0% | 137 | 36.1% |
| Not Yet Recruiting | 83 | 5.3% | 16 | 4.2% |
| Recruiting | 273 | 17.4% | 84 | 22.1% |
| Active Not Recruiting | 78 | 5.0% | 24 | 6.3% |
| Enrolling By Invitation | 20 | 1.3% | 13 | 3.4% |
| Historical | 903 | 57.6% | 202 | 53.2% |
| Completed | 746 | 47.6% | 172 | 45.3% |
| Terminated | 103 | 6.6% | 19 | 5.0% |
| Withdrawn | 39 | 2.5% | 10 | 2.6% |
| Suspended | 9 | 0.6% | 0 | 0.0% |
| No Longer Available | 6 | 0.4% | 1 | 0.3% |
| Unknown | 203 | 12.9% | 41 | 10.8% |

Analysis

• Higher FTD Attrition Rate: The ratio of terminated/withdrawn to completed trials is higher in ALS (142/746 = 19.0%) vs FTD (29/172 = 16.9%), suggesting more ALS programs fail during execution.
• Unknown Status: Both diseases have significant unknown-status trials (12.9% for ALS, 10.8% for FTD), indicating registry maintenance challenges.

Therapeutic Mechanism Coverage

Mechanism Distribution Comparison

| Mechanism Cluster | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---:|---:|---:|---:|
| [Mitochondrial biology](/mechanisms/mitochondrial-dysfunction-ad) | 696 | 44.4% | 47 | 12.4% |
| [Genetic / gene-targeted](/mechanisms/genetic-risk-factors) | 117 | 7.5% | 71 | 18.7% |
| [Amyloid biology](/mechanisms/amyloid-biology) | 74 | 4.7% | 14 | 3.7% |
| [Tau biology](/mechanisms/tau-biology) | 37 | 2.4% | 29 | 7.6% |
| [Tau aggregation](/mechanisms/tau-protein-aggregation) | 37 | 2.4% | 29 | 7.6% |
| [Neuroinflammation](/mechanisms/neuroinflammation) | 14 | 0.9% | 0 | 0.0% |
| [Metal ion dysregulation](/mechanisms/metal-ion-dysregulation) | 14 | 0.9% | 0 | 0.0% |
| [Neurotransmitter systems](/mechanisms/cholinergic-hypothesis-ad) | 0 | 0.0% | 7 | 1.8% |
| [Metabolic pathways](/mechanisms/insulin-resistance-and-metabolic-dysfunction) | 12 | 0.8% | 4 | 1.1% |
| [Synaptic dysfunction](/mechanisms/synaptic-dysfunction) | 0 | 0.0% | 4 | 1.1% |

Mechanism Comparison Visualization

Key Mechanism Insights

Sponsor Landscape Comparison

Sponsor Type Distribution

| Sponsor Type | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---|---:|---:|---:|
| Academic/Medical | 843 | 53.8% | 223 | 58.7% |
| Other | 354 | 22.6% | 89 | 23.4% |
| Industry | 292 | 18.6% | 56 | 14.7% |
| Public (NIH/Gov) | 46 | 2.9% | 10 | 2.6% |
| Foundation/Nonprofit | 33 | 2.1% | 2 | 0.5% |

Analysis

• Academic Dominance: Both diseases are heavily academic-led (53.8% ALS, 58.7% FTD), indicating limited pharmaceutical industry penetration.
• Industry Gap: Industry sponsors only 18.6% of ALS trials and 14.7% of FTD trials—significantly lower than diseases with robust pharma pipelines.
• Foundation Engagement: ALS has 4x more foundation-sponsored trials than FTD (2.1% vs 0.5%), reflecting the strong patient advocacy ecosystem (e.g., ALS Association, ALS Finding a Cure).

Top Sponsors Comparison

| ALS Top Sponsors | Trials | FTD Top Sponsors | Trials |
|---|---:|---|---:|
| Massachusetts General Hospital | 24 | UCSF | 17 |
| Assistance Publique - Hôpitals de Paris | 23 | University of Pennsylvania | 11 |
| Peking University Third Hospital | 22 | Mayo Clinic | 11 |
| Washington University School of Medicine | 16 | Massachusetts General Hospital | 7 |
| Johns Hopkins University | 15 | Nantes University Hospital | 7 |

Key Observations

• US Academic dominance: Both diseases feature major US academic medical centers (MGH, UCSF, UPenn, Mayo) as top sponsors.
• FTD Concentration: FTD research is more concentrated—UCSF alone accounts for 4.5% of all FTD trials.
• International presence: French hospitals (AP-HP, Nantes) appear in both top lists, indicating European engagement.

Funding Gaps and Investment Opportunities

Identified Gaps (Both Diseases)

ALS-Specific Gaps

• Underrepresented mechanisms: Tau biology, neuroinflammation, and metal ion dysregulation represent <3% combined—potential areas for differentiation.
• Biomarker scarcity: Only 7.9% biomarker-forward designs vs 17.6% in FTD.

FTD-Specific Gaps

• Neuroinflammation空白: No registered neuroinflammation trials in FTD, despite growing evidence of microglial involvement.
• Synaptic dysfunction: Only 1.1% of trials target synaptic mechanisms.
• Foundation gap: Near-zero foundation-sponsored trials (0.5%) suggests untapped philanthropy potential.

Cross-Linking to Existing Pages

This analysis should be interpreted alongside:

• [ALS Investment Landscape](/investment/als) — Full ALS trial breakdown
• [FTD Investment Landscape](/investment/ftd) — Full FTD trial breakdown
• [ALS Disease Page](/diseases/amyotrophic-lateral-sclerosis) — Clinical overview of ALS
• [FTD Disease Page](/diseases/frontotemporal-dementia) — Clinical overview of FTD
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum) — Overlapping syndrome
• [Clinical Trials Index](/clinical-trials) — Source data registry

Data Source

This analysis uses the Clinical Trials Index pipeline snapshot from 2026-03-12T04:24:37. For methodology details, see the [Clinical Trials Index](/clinical-trials) page.

See Also

• [ALS Investment Landscape](/investment/als) — Detailed ALS trial analysis
• [FTD Investment Landscape](/investment/ftd) — Detailed FTD trial analysis
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum) — Clinical and pathological overlap
• [Comparative Investment Analysis: AD vs PD](/investment/ad-vs-pd-comparison) — Parallel comparison framework

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Trial registry
• [ALS Association](https://www.als.org/) — Patient advocacy and research
• [The Association for Frontotemporal Degeneration](https://www.theaftd.org/) — FTD resources

References